MedPath

A study on preventing fits in people with stroke by giving Leviteracetam (a drug)

Phase 2
Conditions
Health Condition 1: null- Stroke
Registration Number
CTRI/2017/08/009221
Lead Sponsor
Pondicherry Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Age above 18 years

Patients with acute ischemic stroke (arterial or venous) or parenchymal intracerebral hemorrhage with a cortical syndrome (clinically or imaging wise)

Presenting within one week of an arterial stroke and 2 weeks of confirming a venous thrombosis.

Exclusion Criteria

1. Previous history of epilepsy or treatment with an AED

2. Life expectation less than 1 month due to stroke or other life-threatening comorbidity

3. Subarachnoid or intraventricular hemorrhage

4.Isolated posterior circulation stroke involving brainstem or cerebellum

5. ICVT without cortical syndrome (clinical or radiological)

6. ICH due to brain tumor, trauma, vascular malformation, brain surgery or infection

7. Pre-existing dementia

8.Known allergy to Levieracetam

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurrence of first late epileptic seizure, defined as an unprovoked epileptic seizure more than one week after arterial stroke or two weeks after ICVT.Timepoint: 4 weeks
Secondary Outcome Measures
NameTimeMethod
time from stroke to occurrence of a late epileptic seizure, occurrence of early epileptic seizures after stroke, seizure severity, neurological function, quality of life, midline shift, enlargement of hematoma, death (all cause), functional outcome assessed by Glasgow Outcome Scale and modified Rankin Scale and the occurrence of side effects of the trial medicationTimepoint: 4 weeks
© Copyright 2025. All Rights Reserved by MedPath